Blog
T-knife – unleashing T-cell receptors on cancer – Nature
For 17 years, Thomas Blankenstein has been working on his
September 5, 2021
Menu
For 17 years, Thomas Blankenstein has been working on his
A group of researchers set out to characterize the genotypic
CAR-T cell therapy, which received FDA approval in 2017, are
Solid tumors are surrounded by an immunosuppressive tumor microenvironment. Therefore,
The CAR T-cell therapy idecabtagene vicleucel (ide-cel; Abecma) continues to
Alternative oxidase (AOX) has been identified as a potential therapeutic
The first CAR-T immunotherapy directed against BCMA (idecabtagene vicleucel) for
Australian company, Vaxine Pty Ltd, has developed a protein-based COVID-19
ALLO-501A is a CAR T cell-based therapy for relapsed or
